Stark & Stark attorney Stefanie Colella-Walsh, member of the firm’s Litigation, Insurance Coverage & Liability, Intellectual Property and Mass Torts Groups, was quoted in the New Jersey Law Journal article, “NuvaRing Global Settlement Near as Plaintiffs Close to Opt-In Threshold,” published on April 10, 2014.
The article discusses the $100 million settlement of lawsuits against Merck & Co. over NuvaRing, a product that has been linked to increased blood clots. The settlement was offered by Merck on the condition that 95 percent of claimants accept. Ms. Colella-Walsh was quoted saying that she had “every reason to believe 95 percent will be reached.”
To read the full article, please click here.